Overview of Dr. Drake
Dr. Charles Drake is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from University of Colorado School of Medicine and has been in practice 20 years. Dr. Drake accepts several types of health insurance, listed below. He is one of 368 doctors at New York-Presbyterian Hospital and one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
161 Fort Washington Avenue
New York, NY 10032- Is this information wrong?
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1999 - 2002- Johns Hopkins UniversityResidency, Internal Medicine, 1997 - 1999
University of Colorado School of Medicine Anschutz Medical CampusClass of 1997
Certifications & Licensure
NY State Medical License 2016 - 2024
MD State Medical License 2002 - 2018
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Top Doctors:Baltimore Area Castle Connolly, 2012
- Top Doctors:Washington-Baltimore Castle Connolly, 2012
Clinical Trials
- Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2008 Jul 01
- Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Start of enrollment: 2015 Mar 28
- Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) Start of enrollment: 2018 Oct 11
Publications & Presentations
PubMed
- Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunity.Hong Yu, Hiroshi Nishio, Joseph Barbi, Marisa Mitchell-Flack, Paolo D A Vignali, Ying Zheng, Andriana Lebid, Kwang-Yu Chang, Juan Fu, Makenzie Higgins, Ching-Tai Huang...> ;Biorxiv. 2024 Feb 2
- 1 citationsSMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion.Giuseppe Leuzzi, Alessandro Vasciaveo, Angelo Taglialatela, Xiao Chen, Tessa M Firestone, Allison R Hickman, Wendy Mao, Tanay Thakar, Alina Vaitsiankova, Jen-Wei Huang...> ;Cell. 2024 Feb 15
- Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.Hannah E Bergom, Laura A Sena, Abderrahman Day, Benjamin Miller, Carly D Miller, John R Lozada, Nicholas Zorko, Jinhua Wang, Eugene Shenderov, Francisco Pereira Lobo, ...> ;NPJ Genomic Medicine. 2024 Jan 22
- Join now to see all
Journal Articles
- A Role for Paracrine Interleukin‐6 Signaling in the Tumor Microenvironment in Prostate Tumor GrowthCharles Drake, MD, The Prostate
- And Inflammation in Prostate Cancer InitiationCharles Drake, MD, Development
- Expression of LAG‐3 and Efficacy of Combination Treatment with Anti‐LAG‐3 and Anti‐PD‐1 Monoclonal Antibodies in GlioblastomaCharles Drake, MD, International Journal of Cancer
- Join now to see all
Abstracts/Posters
- Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple MyelomaCharles G Drake, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant...2019 ASCO Annual Meeting - 6/1/2019
- Relationship between sipuleucel-T (sip-T) cytolytic T lymphocyte (CTL) activity and overall survival (OS) in patients (pts) with metastatic castration resistant prosta...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- PD-L1: Prognostic and Predictive State of the Science2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
ASCO21 Preview - Equity: Every Patient. Every Day. EverywhereMay 27th, 2021- VP&S Names 2021 Gerstner ScholarsApril 5th, 2021
CUIMC Celebrates 2019-20, Issue 4February 19th, 2020- Join now to see all
Grant Support
- Role Of Tc17 Cells In Tumor ImmunotherapyNational Cancer Institute2012
- Blockade Of The Immune Checkpoint Mediated By B7-H1 In Men With Prostate CancerNational Cancer Institute2008–2011
- Analysis Of LAG-3 In Regulatory T Cell Function And Immune SupressionNational Cancer Institute2008–2011
- Regulation Of The Immune Response To Prostate CancerNational Cancer Institute2003–2007
Professional Memberships
- Member
Hospital Affiliations
New York-Presbyterian HospitalNew York, New York
NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/charles-drake
Insurance Accepted
- BCBS Blue Card PPO
CareFirst BCBS Maryland POS
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOFirst Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
